Technology Platform

Genome Editing and Epigenetic Modification Platform、Ex vivo Rapid Expansion Platform、Ex vivo Rapid Evaluation Platform for Cell Therapeutics、Non-viral Transfection Platform

Genome Editing and Epigenetic Modification Platform

Using CRISPR editing technology, we can edit and modify the DNA or RNA of human ···

View more

Genome Editing and Epigenetic Modification Platform

In vitro rapid amplification platform

Rapid large-scale culture of immune cells (T cells and NK cells) and stem cells ···

View more

In vitro rapid assessment platform for cellular drugs

A rapid in vitro evaluation system utilizing multidisciplinary technologies such···

View more

In vitro rapid assessment platform for cellular drugs

About Us

Innovating biotechnology for the betterment of human health.

Chengdu MedGenCell Co., Ltd

ChengduMedGenCellCo.,Ltd (hereafter referred to as "the Company") was established in 2015. It is a technology enterprise primarily engaged in the research and development of cutting-edge pre...

Established in 2015

700+

700 sq ft GMP laboratory

20+

Core R&D Team

4Item

Pipeline under development

2Vice

Access to top provincial/city innovation and entrepreneurship teams

10+

National Invention Patent

HONORARY QUALIFICATION

Awards and Qualifications

Sichuan Thousand Talents Program Special Expert-Deng Tao

Chengdu Talent Program Special Expert-Deng Tao

Sichuan Top Innovation and Entrepreneurship Team

Chengdu Top Innovation and Entrepreneurship Team

Chengdu Hi-tech Zone Innovation and Entrepreneurship Talent Award

State-level science and technology-based small and medium-sized enterprises

Zero2IPO Group's Top 50 Most Valuable Companies for Investment in China 2018

Top Ten Quality Biotechnology Enterprises

Western China SME Development Forum Think Tank Expert-Deng Tao

News

02-01 2024

MedGenCell's PD-1 Gene-Edited T Cell Injection Approved for Clinical Trials

According to the CDE official website, MedGencell (Beijing) Co., Ltd(hereinafter referred to as "Med···

11-17 2023

Milestone: World's First CRISPR Gene Editing Therapy Approved in the UK!

On November 16, the world's first CRISPR gene editing therapy (Exa-cel, CASGEVY™) received conditio···

10-23 2022

First clinical trial application for gene-edited T-cell drug for solid tumors formally accepted by State Drug Administration (SDA)

According to the open literature, its “PD-1 gene-edited T-cell injection” IIT phase I clinical tri···

10-17 2022

Embracing the 20th National Congress: Talents United with the Party, Pursuing Dreams in the New Era

On the eve of the 20th National Congress of the Party, the Chengdu Rongdrifters Talent Comprehensive···

07-02 2021

Voices of ”Rongpiao" Talents | Deng Tao: Science Has No Borders, But Scientists Have a Motherland

To celebrate the 100th anniversary of the founding of the Communist Party of China, on June 26th, th···

02-18 2021

The article co-authored by Dr. Deng Tao and the GCP Center of the Chinese Academy of Medical Sciences has been published in CANCER CELL, a sub-journal of Cell.

On January 12, 2021, the article co-authored by Dr. Deng Tao and the National Cancer Center/Cancer H···

address：603-604, Building 4, Hitech International Plaza, No.1 Ke Yuan South Road, Hi-Tech Zone, Chengdu, China
mobile phones：028-85176377
telephones：13880324785
email：wangxueding@medgencell.com

Scan the code to contact us

Technical Support：Sckingme